| Preferred# | Alternative¶ | Not recommended | Total n | |
| Bratislava, Slovakia | 29 (11.1) | 193 (73.7) | 40 (15.3) | 262 |
| Balatonfured, Hungary | 57 (23.7) | 130 (53.9) | 54 (22.4) | 241 |
| Lodz, Poland | 65 (30.2) | 119 (55.3) | 31 (14.4) | 215 |
| Cardiff, UK | 163 (78.0) | 36 (17.2) | 10 (4.8) | 209 |
| Milan, Italy | 15 (9.7) | 121 (78.1) | 19 (12.3) | 155 |
| Southampton, UK | 112 (83.6) | 12 (9.0) | 10 (7.5) | 134 |
| Jönköping, Sweden | 76 (66.7) | 7 (6.1) | 31 (27.2) | 114 |
| Utrecht, the Netherlands | 74 (89.2) | 7 (8.4) | 2 (2.4) | 83 |
| Rotenburg, Germany | 45 (57.0) | 21 (26.6) | 13 (16.5) | 79 |
| Mataro, Spain | 12 (17.9) | 51 (76.1) | 4 (6.0) | 67 |
| Tromsø, Norway | 31 (50.8) | 9 (14.8) | 21 (34.4) | 61 |
| Barcelona, Spain | 15 (26.3) | 42 (73.7) | 0 (0.0) | 57 |
| Antwerp, Belgium | 38 (67.9) | 14 (25.0) | 4 (7.1) | 56 |
| Helsinki, Finland | 29 (67.4) | 11 (25.6) | 3 (7.0) | 43 |
| Total | 761 (42.8) | 773 (43.5) | 242 (13.6) | 1776 |
Data are presented as n (%), unless otherwise stated. ERS: European Respiratory Society; ESCMID: European Society of Clinical Microbiology and Infectious Diseases. #: amoxicillin and tetracycline; ¶: macrolides, amoxicillin–clavulanate, levofloxacillin and moxifloxacin.